AZN’s Tagrisso was already selling at an annualized rate of ~$6B before the ADAURA trial read out, and we can presume that sales are heading even higher.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.